By blocking dopamine-1 receptors, ecopipam is expected to reduce the repetitive and compulsive behaviors seen in Tourette syndrome.

Emalex Biosciences’ dopamine blocker led to fewer patients with Tourette syndrome relapsing in a phase 3 trial, setting the stage for the Chicago-based firm to submit the drug candidate for ...

A recent study from Stanford’s Wu Tsai Neurosciences Institute has shed light on the interplay between two key brain chemicals, dopamine and serotonin, revealing their opposing roles in shaping ...

What we previously didn’t know is that the dopamine blockers aimed at treating hallucinations and delusions may also help with their mentalising abilities. Our study will hopefully pave the way ...

During the double-blind withdrawal period, 41.9% of ecopipam-treated patients relapsed compared with 68.1% of placebo-treated patients. Topline data were announced from a phase 3 trial evaluating ...